2020
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.Peer-Reviewed Original ResearchConceptsDelayed-release dimethyl fumarateAbsolute lymphocyte countT cellsMedian absolute lymphocyte countEffector memory T cellsDimethyl fumarate treatmentPhase 3b studyTotal T cellsAdverse event ratesMemory T cellsProtective humoral immunityForms of MSDMF BIDLymphocyte subsetsAdverse eventsLymphocyte countTotal IgAImmune environmentImmunoglobulin levelsNaive CD4Sustained efficacyHumoral immunityFumarate treatmentSubclass levelsCount changes
2016
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Longbrake EE, Cross AH. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. JAMA Neurology 2016, 73: 1-7. PMID: 26720195, DOI: 10.1001/jamaneurol.2015.3977.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesB cell immunityB cellsMultiple sclerosisAnti-inflammatory cytokine interleukin-10B-cell-depleting agentsMultiple Sclerosis Disease-Modifying TherapiesMost disease-modifying therapiesCytokine interleukin-10Memory B cellsB cell functionB-cell phenotypeB cell expressionB cell productionNaive B cellsMagnetic resonance imagingB cell precursorsClinical courseTherapeutic trialsInterleukin-10Proinflammatory cytokinesHumoral immunityClinical activityTherapeutic interventionsResonance imaging